glp-1 post bariatric surgery hypoglycemia Potential mechanisms contributing to post-bariatric Role of Glucagon-Like Peptide-1 (GLP-1)

L-lysine or its organic acid salts or inorganic, exerts a potentiating or synergistic effect vis--vis the biological effects of L-carnitine

SURMOUNT-5 trial shows Tirzepatide beats Semaglutide with 20.2% vs 13.7% weight loss

side effects in non-diabetic users The side-effect conversation gets more complicated when you dont have diabetes, because youre accepting risk for a drug you dont medically require

The following features would enhance the value of an obesity therapeutic, but would likely be assessed in follow-up trials or even post-approval: Additional efficacy in obesity-related co-morbidities

About 8% of patients who switch to tirzepatide return to semaglutide due to intolerance

The mechanism is plausible